First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

David Adams, Ole B. Suhr, Ernst Hund, Laura Obici, Ivailo Tournev, Josep M. Campistol, Michel S. Slama, Bouke P. Hazenberg, Teresa Coelho

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Early and accurate diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) represents one of the major challenges faced by physicians when caring for patients with idiopathic progressive neuropathy. There is little consensus in diagnostic and management approaches across Europe. RECENT FINDINGS: The low prevalence of TTR-FAP across Europe and the high variation in both genotype and phenotypic expression of the disease means that recognizing symptoms can be difficult outside of a specialized diagnostic environment. The resulting delay in diagnosis and the possibility of misdiagnosis can misguide clinical decision-making and negatively impact subsequent treatment approaches and outcomes. SUMMARY: This review summarizes the findings from two meetings of the European Network for TTR-FAP (ATTReuNET). This is an emerging group comprising representatives from 10 European countries with expertise in the diagnosis and management of TTR-FAP, including nine National Reference Centres. The current review presents management strategies and a consensus on the gold standard for diagnosis of TTR-FAP as well as a structured approach to ongoing multidisciplinary care for the patient. Greater communication, not just between members of an individual patientʼs treatment team, but also between regional and national centres of expertise, is the key to the effective management of TTR-FAP.

Original languageEnglish
JournalCurrent Opinion in Neurology
DOIs
Publication statusAccepted/In press - Jan 5 2016

Fingerprint

Familial Amyloid Neuropathies
Prealbumin
Consensus
Therapeutics
Diagnostic Errors
Early Diagnosis
Patient Care
Communication
Genotype
Physicians

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. / Adams, David; Suhr, Ole B.; Hund, Ernst; Obici, Laura; Tournev, Ivailo; Campistol, Josep M.; Slama, Michel S.; Hazenberg, Bouke P.; Coelho, Teresa.

In: Current Opinion in Neurology, 05.01.2016.

Research output: Contribution to journalArticle

Adams, David ; Suhr, Ole B. ; Hund, Ernst ; Obici, Laura ; Tournev, Ivailo ; Campistol, Josep M. ; Slama, Michel S. ; Hazenberg, Bouke P. ; Coelho, Teresa. / First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. In: Current Opinion in Neurology. 2016.
@article{cafbad369ef14374b349866d19ac0924,
title = "First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy",
abstract = "PURPOSE OF REVIEW: Early and accurate diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) represents one of the major challenges faced by physicians when caring for patients with idiopathic progressive neuropathy. There is little consensus in diagnostic and management approaches across Europe. RECENT FINDINGS: The low prevalence of TTR-FAP across Europe and the high variation in both genotype and phenotypic expression of the disease means that recognizing symptoms can be difficult outside of a specialized diagnostic environment. The resulting delay in diagnosis and the possibility of misdiagnosis can misguide clinical decision-making and negatively impact subsequent treatment approaches and outcomes. SUMMARY: This review summarizes the findings from two meetings of the European Network for TTR-FAP (ATTReuNET). This is an emerging group comprising representatives from 10 European countries with expertise in the diagnosis and management of TTR-FAP, including nine National Reference Centres. The current review presents management strategies and a consensus on the gold standard for diagnosis of TTR-FAP as well as a structured approach to ongoing multidisciplinary care for the patient. Greater communication, not just between members of an individual patientʼs treatment team, but also between regional and national centres of expertise, is the key to the effective management of TTR-FAP.",
author = "David Adams and Suhr, {Ole B.} and Ernst Hund and Laura Obici and Ivailo Tournev and Campistol, {Josep M.} and Slama, {Michel S.} and Hazenberg, {Bouke P.} and Teresa Coelho",
year = "2016",
month = "1",
day = "5",
doi = "10.1097/WCO.0000000000000289",
language = "English",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

AU - Adams, David

AU - Suhr, Ole B.

AU - Hund, Ernst

AU - Obici, Laura

AU - Tournev, Ivailo

AU - Campistol, Josep M.

AU - Slama, Michel S.

AU - Hazenberg, Bouke P.

AU - Coelho, Teresa

PY - 2016/1/5

Y1 - 2016/1/5

N2 - PURPOSE OF REVIEW: Early and accurate diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) represents one of the major challenges faced by physicians when caring for patients with idiopathic progressive neuropathy. There is little consensus in diagnostic and management approaches across Europe. RECENT FINDINGS: The low prevalence of TTR-FAP across Europe and the high variation in both genotype and phenotypic expression of the disease means that recognizing symptoms can be difficult outside of a specialized diagnostic environment. The resulting delay in diagnosis and the possibility of misdiagnosis can misguide clinical decision-making and negatively impact subsequent treatment approaches and outcomes. SUMMARY: This review summarizes the findings from two meetings of the European Network for TTR-FAP (ATTReuNET). This is an emerging group comprising representatives from 10 European countries with expertise in the diagnosis and management of TTR-FAP, including nine National Reference Centres. The current review presents management strategies and a consensus on the gold standard for diagnosis of TTR-FAP as well as a structured approach to ongoing multidisciplinary care for the patient. Greater communication, not just between members of an individual patientʼs treatment team, but also between regional and national centres of expertise, is the key to the effective management of TTR-FAP.

AB - PURPOSE OF REVIEW: Early and accurate diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) represents one of the major challenges faced by physicians when caring for patients with idiopathic progressive neuropathy. There is little consensus in diagnostic and management approaches across Europe. RECENT FINDINGS: The low prevalence of TTR-FAP across Europe and the high variation in both genotype and phenotypic expression of the disease means that recognizing symptoms can be difficult outside of a specialized diagnostic environment. The resulting delay in diagnosis and the possibility of misdiagnosis can misguide clinical decision-making and negatively impact subsequent treatment approaches and outcomes. SUMMARY: This review summarizes the findings from two meetings of the European Network for TTR-FAP (ATTReuNET). This is an emerging group comprising representatives from 10 European countries with expertise in the diagnosis and management of TTR-FAP, including nine National Reference Centres. The current review presents management strategies and a consensus on the gold standard for diagnosis of TTR-FAP as well as a structured approach to ongoing multidisciplinary care for the patient. Greater communication, not just between members of an individual patientʼs treatment team, but also between regional and national centres of expertise, is the key to the effective management of TTR-FAP.

UR - http://www.scopus.com/inward/record.url?scp=84953274437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953274437&partnerID=8YFLogxK

U2 - 10.1097/WCO.0000000000000289

DO - 10.1097/WCO.0000000000000289

M3 - Article

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

ER -